Jump to content
  • rrdiLogo384x64.jpg

    We are rosaceans and this is a grassroots rosacea non profit organization. Finding the Cure for rosacea. If you like to read, scroll down to the bottom. If you prefer videos, scroll down to view all the videos about the RRDi. What's with the butterfly? We need 100 Active Subscribers! To learn more about the RRDi watch the videos by scrolling below, or if you prefer reading, keep scrolling. 

      Become a Patron!

    Join the most private rosacea community on the web!

    Videos & RRDi Social Media Accounts

  • Forum Statistics

    • Total Topics
    • Total Posts
  • The Rosacea Research & Development Institute [RRDi] is the first 501 (c) (3) non profit organization approved by the IRS established June 7, 2004 in the State of Hawaii, USA for the purpose of finding a cure for rosacea, researching rosacea, and to form a rosacea patient advocacy organization established by volunteer rosaceans for rosacea sufferers. In December 2019 we have moved the corporate office to the State of Alabama and have registered as a non profit corporation.

    Our non profit organization for rosacea patient advocacy web site is a digital data repository of rosacea information that can serve you personally as an armamentarium of rosacea treatment options. We have tools to help you in your search for a cure to rosacea, or at least a way to control it.

    We have chosen the Invision Community as the chief digital platform tool (with beta versions for Android and iOS mobile apps) to use, a public platform for guests and inactive members. Our member forum is the most private forum for rosacea on the internet. We also have a private platform using Tapatalk using our rosacea-control.com domain. 

    We are rosacea sufferers [rosaceans] and all are volunteers. We rely on donations. No one is receiving a salary or getting paid. We don't spend donated funds on private contractors that are owned by any member of the board of directors. We do not spend donated funds so our members can attend dermatology conventions. All donations are spent on keeping this non profit organization for rosacea sufferers a viable patient advocacy organization and our rules state that 'members may not profit from the institute' (rule number 3). Read our mission statement

    No one has a paid salary, we pay NO private contractors nor do we use donations so our members can attend dermatology conventions. 

    All the other rosacea non profits are not run by rosacea sufferers (see Other Non Profit Rosacea Organizations on this page). Check out the other non profit organizations for rosacea, discover for yourself and you will find out who serve on the board of directors (non rosaceans - dermatologists/businessmen) and then simply follow the money (what does the organization spend most of the donated money on?) and discover for yourself that the other non profit organizations for rosacea spend most of the donations on (1) private contractors, (2) dermatologist member conventions or (3) salaries. We have no special interest other than finding the cure for rosacea and forming a rosacea patient advocacy organization. Our non profit has no salaries, no spending on private contractors, no expenses for member conventions. Follow the money (this is where we spend our money). Notice where most of the money is spent with another rosacea non profit, who has spent millions of dollars on private contractors owned by the president of the non profit and only 10% on rosacea research. 

    Read our Misson Statement and see if you agree? If you suffer from rosacea, this is the rosacea non profit to join. Your membership increases our impact on the medical community. Our goal is to reach 10,000 members. Please join and help us reach our goal. What if 10,000 members got together and each donated one dollar and all the members agreed we should sponsor a certain rosacea research study. Is this possible? Only with your help. 

    You may want to read our post about Anonymity, Transparency and Posting before joining. We have now switched to a subscription member service

    The logo of the RRDi includes a butterfly because rosacea typically manifests itself in a facial butterfly formation, however the irony of the butterfly effect is apropros. Learn More.

    You may want to learn about the history of this non profit or why it was formed

    If you are a rosacean, volunteer by joining our private member forum and posting or in our public guest forum (registration required) becoming a part of 'finding the cure' for rosacea if you join. Our goal is 10,000 members. Membership is free. You can help us reach our goal by joining with just your email address.  if privacy is of paramount importance to you use Sign in with Apple and join our private member forum. Or you can simply browse our web site and guest forum for free. Our non profit affiliate store is another source of rosacea treatment options. 

    If you want to post about your rosacea, we certainly allow you to post feedback in our GUEST forum or register an account in our member forum, i.e,, in our public community support, and, if you want to learn about and treat your rosacea, this is the best non profit organization for rosacea sufferers. At the social networks like Facebook, Instagram or Reddit can you find the incredible digital tools the RRDi provides free to its members or the ability to find what you are searching for in rosacea research? Are you able through such social media groups to influence the medical community how you feel about rosacea? Read our mission statement and compare with your private rosacea social media group, i.e., like Facebook, Instagram or Reddit.  

    The RRDi is registered at GuideStar and Trustpilot • Write a Review of Our Non Profit

  • Member Statistics

    Total Members
    Most Online
    Newest Member

  • Registered with the Internal Revenue Service of the USA


    EIN 20-1259275

  • 240px-Seal_of_Alabama.svg.png

  • Alabama Secretary of State Certification

    Entity Identification Number 596-247

  • Posts

    • Expert Rev Clin Immunol. 2022 Sep 22. doi: 10.1080/1744666X.2022.2128334. Online ahead of print. ABSTRACT INTRODUCTION: : Recent advances in the understanding of the pathophysiology of rosacea have led to increased focus on the disease's immunologic etiology and to the development of immunologically based treatments. With many patients suffering from incomplete control, addressing the immune components of the disease process may provide a more effective treatment option for rosacea patients that may improve quality of life. AREAS COVERED: : This review will provide a brief overview of the pathophysiology or rosacea, as well as specific immunologic contributions to the disease state. Current standard-of-care treatments will be described, including anti-parasitic, anti-inflammatory agents, and antibiotics. Emphasis will be placed on treatments that target the immune components of the disease process. EXPERT OPINION: : Rosacea remains a difficult dermatologic disease to treat, partially due to an incomplete understanding of the disease pathophysiology. The immune pathophysiology of rosacea, particularly the key role of inflammation, has been clarified over the past decade. Identification of specific molecules, including cytokines and nuclear transcription factors, may allow for the development of targeted rosacea-specific biologic and topical treatments. However, medication nonadherence is a limiting factor to achieving symptomatic control among rosacea patients. Focusing on the development of oral or injectable forms of therapy may circumvent poor adherence. PMID:36137266 | DOI:10.1080/1744666X.2022.2128334 {url} = URL to article
    • J Cosmet Dermatol. 2022 Sep 20. doi: 10.1111/jocd.15271. Online ahead of print. NO ABSTRACT PMID:36126208 | DOI:10.1111/jocd.15271 {url} = URL to article
    • JAAD Case Rep. 2022 Jul 19;28:83-86. doi: 10.1016/j.jdcr.2022.07.014. eCollection 2022 Oct. NO ABSTRACT PMID:36105757 | PMC:PMC9467856 | DOI:10.1016/j.jdcr.2022.07.014 {url} = URL to article
    • Cureus. 2022 Sep 3;14(9):e28726. doi: 10.7759/cureus.28726. eCollection 2022 Sep. ABSTRACT Facial hypervascularity is a condition that manifests as erythema and edema caused by aberrant blood vessels. Often, the cause of these abnormal blood vessels can be attributed to previous trauma or vascular conditions such as rosacea, although sometimes the cause is unknown. Pulsed dye laser (PDL) can be an effective treatment even when the cause is unknown. We present a case of a 24-year-old male presenting with intermittent swelling, redness, and throbbing sensations of the nose and cheeks for the past five years. Physical examination was notable for prominent erythema and swelling of the nasal skin and mild erythema on the cheeks. He underwent treatment with PDL and achieved complete resolution of his symptoms. This case illustrates the effectiveness of PDL in the treatment of facial hypervascularity. PMID:36105901 | PMC:PMC9447474 | DOI:10.7759/cureus.28726 {url} = URL to article
    • J Dtsch Dermatol Ges. 2022 Sep 13. doi: 10.1111/ddg.14879. Online ahead of print. ABSTRACT This guideline aims to improve the efficiency and safety of lasers and optical radiation sources with similar effects (especially IPL). Laser therapy of skin lesions with an increased amount of melanocytes should be performed with caution. Laser treatment of pigmented melanocytic nevi is not recommended. The guideline contains recommendations regarding the treatment of lentigines and café-au-lait spots, non-pigmented dermal nevi, Becker nevus, nevus of Ota/Hori/Ito and melasma. Further recommendations focus on the treatment of skin lesions without an increased amount of melanocytes (ephelides, postinflammatory hyperpigmentation including berloque dermatitis, seborrheic keratoses, traumatic/decorative tattoos and metallic deposits), hypopigmentation (vitiligo), benign non-pigmented neoplasms (fibrous papule of the nose, nevus sebaceus, epidermal nevus, neurofibroma, sebaceous gland hyperplasia, syringoma, xanthelasma palpebrarum), inflammatory dermatoses (acne papulopustulosa/conglobata, acne inversa, granuloma faciale, lichen sclerosus, lupus erythematosus, psoriasis vulgaris, rosacea, rhinophyma), wrinkles/dermatochalasis/striae, hypertrichosis, scars (atrophic, hypertrophic; keloids, burn/scald scars), laser-assisted skin healing, onychomycosis, precancerous lesions and malignant tumors (actinic keratoses/field cancerization, cheilitis actinica, basal cell carcinoma), vascular skin lesions (angiokeratoma, angioma, hemangioma, malformation, spider veins, granuloma telangiectaticum (pyogenic granuloma), rubeosis (erythrosis interfollicularis colli, ulerythema ophryogenes), nevus flammeus, telangiectasias and Osler's disease (hereditary hemorrhagic telangiectasia) and viral skin lesions (condylomata acuminata, mollusca contagiosa, verrucae planae juveniles/vulgares/ verrucae palmares et plantares). PMID:36098675 | DOI:10.1111/ddg.14879 {url} = URL to article
    • Dermatol Ther (Heidelb). 2022 Sep 13. doi: 10.1007/s13555-022-00798-8. Online ahead of print. NO ABSTRACT PMID:36098878 | DOI:10.1007/s13555-022-00798-8 {url} = URL to article
    • J Cosmet Dermatol. 2022 Sep 13. doi: 10.1111/jocd.15384. Online ahead of print. ABSTRACT BACKGROUND: Rosacea is a chronic inflammatory skin disease affecting the face, and the current treatment effect is not satisfactory. Based on the photomodulation of optimal pulse technology (OPT), we developed a novel treatment mode, namely, advanced OPT with low energy, three pulses, and long pulse width (AOPT-LTL). AIMS: We aimed to explore the feasibility and underlying molecular mechanisms of AOPT-LTL treatment in a rosacea-like mouse model. Furthermore, we evaluated the safety and efficacy in patients with erythematotelangiectatic rosacea (ETR). MATERIALS AND METHODS: Morphological, histological, and immunohistochemical analyses were used to investigate the efficacy and mechanisms of AOPT-LTL treatment in the LL-37-induced rosacea-like mouse model. Moreover, twenty-three patients with ETR were included and received different times of treatment at intervals of two weeks depending on the severity of their condition. The treatment effect was assessed by comparing clinical photographs at baseline, one week and three months after treatment, combined with the red value, GFSS, and CEA scores. RESULTS: After the AOPT-LTL treatment of the mice, we observed that the rosacea-like phenotype, inflammatory cell infiltration, and vascular abnormalities were significantly ameliorated, and the expression of the core molecules of rosacea was significantly inhibited. In the clinical study, the AOPT-LTL treatment exerted satisfactory therapeutic effects on erythema and flushing of ETR patients. No serious adverse events were observed. CONCLUSIONS: AOPT-LTL is a safe and effective method for the treatment of ETR. PMID:36099436 | DOI:10.1111/jocd.15384 {url} = URL to article
    • Dermatol Ther. 2022 Sep 12:e15819. doi: 10.1111/dth.15819. Online ahead of print. ABSTRACT OBJECTIVE: Brimonidine is a vasoconstrictive agent used to treat several dermatologic disorders. Here, we review the uses of brimonidine in different aspects of dermatology. METHODS: We searched keywords including rosacea, erythema, topical brimonidine, dermatology, and skin disease in PubMed, Cochrane, and Google Scholar to collect the related published articles. RESULTS: In a review of 15 articles, we found topical brimonidine improved the facial erythema of rosacea. In addition, it reduced the erythema associated with alcohol flushing syndrome, intense pulsed light therapy, and photodynamic therapy. Furthermore, topical brimonidine was used as a hemostatic agent in dermatosurgery procedures such as Mohs surgery and nail surgery to reduce intra-operative and postoperative bleeding. Some side effects such as erythema, flushing, and burning were reported in a few patients. CONCLUSION: Based on our findings, brimonidine is a beneficial drug that can be used in various dermatologic disorders with negligible side effects. This article is protected by copyright. All rights reserved. PMID:36097378 | DOI:10.1111/dth.15819 {url} = URL to article
    • Front Immunol. 2022 Aug 24;13:985081. doi: 10.3389/fimmu.2022.985081. eCollection 2022. ABSTRACT BACKGROUND: In recent years, frontal fibrosing alopecia (FFA), a type of scarring alopecia, has attracted increasing attention. Several studies have reported the frequent occurrence of rosacea in FFA; however, the association between FFA and rosacea and the underlying pathogenesis have not been thoroughly clarified. Thus, this study aimed to quantify these relationships and investigate their shared molecular mechanisms. METHODS: We evaluated the association between FFA and rosacea by analyzing clinical data from nine observational studies. We then analyzed the gene expression profiles of FFA and rosacea. First, differential expression analysis and weighted gene co-expression network analysis were used to identify the common differentially expressed genes (DEGs). Later, we conducted a functional enrichment analysis and protein-protein interaction network and used seven algorithms to identify hub genes. Then, we performed a correlation analysis between the hub genes and the gene set variation analysis scores of common pathways in the gene set enrichment analysis (GSEA). The results were validated using different datasets. Finally, transcription factors were predicted and verified, and CIBERSORT and single-sample GSEA were used to estimate the infiltrating immune cells. RESULTS: Patients with FFA had significantly higher odds for rosacea (pooled odds ratio [OR], 2.46; 95% confidence interval [CI], 1.78-3.40), and the pooled prevalence of rosacea in patients with FFA was 23% (95% CI, 14-23%). Furthermore, we identified 115 co-DEGs and 13 hub genes (CCR5, CCL19, CD2, CD38, CD83, CXCL8, CXCL9, CXCL10, CXCL11, CXCR4, IRF1, IRF8, and PTPRC). Seven pathways showed a high correlation with these hub genes. In addition, one TF, STAT1, was highly expressed in both diseases, and the results of the immune infiltration analysis indicated the importance of M1 macrophages and effector memory CD8+ T cells. CONCLUSION: This study contributes to the understanding of the relationship between FFA and rosacea, and based on the hub genes, we reveal the potential pathologies shared by the two diseases. This finding provides new insights of underlying molecular mechanisms and it may inspire future research on this comorbidity. PMID:36091020 | PMC:PMC9448884 | DOI:10.3389/fimmu.2022.985081 {url} = URL to article
  • Create New...

Important Information

Terms of Use